Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibody–Associated Disease - Aix-Marseille Université Access content directly
Journal Articles Neurology Year : 2022

Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibody–Associated Disease

Louisa M Schöppe
  • Function : Author
Judith Bellmann-Strobl
Nadja Siebert
  • Function : Author
Friedemann Paul
  • Function : Author
Ankelien Duchow
Hannah Pellkofer
  • Function : Author
Tania Kümpfel
  • Function : Author
Joachim Havla
Sven Jarius
  • Function : Author
Brigitte Wildemann
  • Function : Author
Achim Berthele
Florian Then Bergh
  • Function : Author
Marc Pawlitzki
  • Function : Author
Luisa Klotz
Ingo Kleiter
Martin Stangel
  • Function : Author
Stefan Gingele
  • Function : Author
Martin S Weber
  • Function : Author
Juergen H Faiss
  • Function : Author
Refik Pul
  • Function : Author
Annette Walter
  • Function : Author
Uwe K Zettl
  • Function : Author
Makbule Senel
  • Function : Author
Vivien Häußler
Kerstin Hellwig
Ilya Ayzenberg
  • Function : Author
Orhan Aktas
Marius Ringelstein
  • Function : Author
Olivia Schreiber-Katz
Corinna Trebst
  • Function : Author
  • PersonId : 1221182

Abstract

Background and Objectives To evaluate costs and health-related quality of life (HRQoL) of neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Methods In this multicenter cross-sectional study, data on consumption of medical and nonmedical resources and work ability were assessed via patient questionnaires. Costs were analyzed in Euros for 2018 from the societal perspective. HRQoL was captured by the EuroQoL Group 5 Dimension 5 Level Scale (EQ-5D-5L) questionnaire. Clinical data were retrieved from the Neuromyelitis Optica Study Group (NEMOS) database. Results Two hundred twelve patients (80% women, median age 50 [19-83] years, median disease duration 7 [0-43] years, median Expanded Disability Status Scale [EDSS] score 3.5 [0-8.5], 66% aquaporin-4 immunoglobulin G [IgG] positive, 22% MOG IgG positive, 12% double seronegative) were analyzed. The mean total annual per capita cost of illness accounted for €59,574 (95% CI 51,225-68,293 or US dollars [USD] 70,297, 95% CI 60,445-80,586), and the mean index value of the EQ-5D-5L was 0.693 (95% CI 0.65-0.73). The most important cost drivers were informal care costs (28% of total costs), indirect costs (23%), and drugs (16%),
Fichier principal
Vignette du fichier
hummert-neurology-2022.pdf (736.78 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive

Dates and versions

hal-03962701 , version 1 (30-01-2023)

Identifiers

Cite

Martin W Hümmert, Louisa M Schöppe, Judith Bellmann-Strobl, Nadja Siebert, Friedemann Paul, et al.. Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibody–Associated Disease. Neurology, 2022, 98, pp.e1184 - e1196. ⟨10.1212/wnl.0000000000200052⟩. ⟨hal-03962701⟩
5 View
5 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More